Atrial Fibrillation and Risk of ST-Segment–Elevation Versus Non–ST-Segment–Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study

Background— It has recently been reported that atrial fibrillation (AF) is associated with an increased risk of myocardial infarction (MI). However, the mechanism underlying this association is currently unknown. Further study of the relationship of AF with the type of MI (ST-segment–elevation MI [STEMI] versus non–ST-segment–elevation MI [NSTEMI]) might shed light on the potential mechanisms. Methods and Results— We examined the association between AF and incident MI in 14 462 participants (mean age, 54 years; 56% women; 26% blacks) from the Atherosclerosis Risk in Communities (ARIC) study who were free of coronary heart disease at baseline (1987–1989) with follow-up through December 31, 2010. AF cases were identified from study visit ECGs and by review of hospital discharge records. Incident MI and its types were ascertained by an independent adjudication committee. Over a median follow-up of 21.6 years, 1374 MI events occurred (829 NSTEMIs, 249 STEMIs, 296 unclassifiable MIs). In a multivariable-adjusted model, AF (n=1545) as a time-varying variable was associated with a 63% increased risk of MI (hazard ratio,1.63; 95% confidence interval, 1.32–2.02). However, AF was associated with NSTEMI (hazard ratio, 1.80; 95% confidence interval, 1.39–2.31) but not STEMI (hazard ratio, 0.49; 95% confidence interval, 0.18–1.34; P for hazard ratio comparison=0.004). Combining the unclassifiable MI group with either STEMI or NSTEMI did not change this conclusion. The association between AF and MI, total and NSTEMI, was stronger in women than in men (P for interaction <0.01 for both). Conclusions— AF is associated with an increased risk of incident MI, especially in women. However, this association is limited to NSTEMI.

[1]  Stephen S. Cha,et al.  Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, 1980 to 2000, and Implications on the Projections for Future Prevalence , 2006, Circulation.

[2]  Timothy Watson,et al.  Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited , 2009, The Lancet.

[3]  Ronald J. Prineas,et al.  The Minnesota code manual of electrocardiographic findings : standards and procedures for measurement and classification , 1982 .

[4]  D. Knopman,et al.  The Metabolic Syndrome and Cognitive Decline in the Atherosclerosis Risk in Communities Study (ARIC) , 2014, Dementia and Geriatric Cognitive Disorders.

[5]  James Floyd,et al.  A systematic review of validated methods for identifying atrial fibrillation using administrative data , 2012, Pharmacoepidemiology and drug safety.

[6]  Elsayed Z Soliman,et al.  Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. , 2009, American heart journal.

[7]  C. Moy,et al.  The Sensitivity of the Method Used to Detect Atrial Fibrillation in Population Studies Affects Group-Specific Prevalence Estimates: Ethnic and Regional Distribution of Atrial Fibrillation in the REGARDS Study , 2009, Journal of epidemiology.

[8]  P. Vardas,et al.  Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. , 2007, The American journal of cardiology.

[9]  A. Folsom,et al.  Coronary heart disease risk prediction in the Atherosclerosis Risk in Communities (ARIC) study. , 2003, Journal of clinical epidemiology.

[10]  G. Lip,et al.  Inflammation in atrial fibrillation. , 2012, Journal of the American College of Cardiology.

[11]  M. Russo,et al.  Histological substrate of atrial biopsies in patients with lone atrial fibrillation. , 1997, Circulation.

[12]  A. Folsom,et al.  Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience. , 1996, Journal of clinical epidemiology.

[13]  J. Carrero,et al.  Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. , 2014, JAMA.

[14]  G. Marcus,et al.  Atrial fibrillation begets myocardial infarction. , 2014, JAMA internal medicine.

[15]  Joel Stein,et al.  Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. , 2014, Circulation.

[16]  A. Folsom,et al.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. , 1989, American journal of epidemiology.

[17]  J. Cook,et al.  Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit , 2005, Annals of Internal Medicine.

[18]  Sonia S Anand,et al.  Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. , 1999, JAMA.

[19]  M Lunn,et al.  Applying Cox regression to competing risks. , 1995, Biometrics.

[20]  K. Toyama,et al.  Endothelial dysfunction in paroxysmal atrial fibrillation as a prothrombotic state. Comparison with permanent/persistent atrial fibrillation. , 2011, Journal of atherosclerosis and thrombosis.

[21]  Ralph B D'Agostino,et al.  A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. , 2003, JAMA.

[22]  Zhu-ming Zhang,et al.  Ethnic Distribution of ECG Predictors of Atrial Fibrillation and Its Impact on Understanding the Ethnic Distribution of Ischemic Stroke in the Atherosclerosis Risk in Communities (ARIC) Study , 2009, Stroke.

[23]  E. Benjamin,et al.  Status of the epidemiology of atrial fibrillation. , 2008, The Medical clinics of North America.

[24]  V. Howard,et al.  Racial Disparities in Awareness and Treatment of Atrial Fibrillation: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study , 2010, Stroke.

[25]  M. Hori,et al.  Plasma levels of nitrite/nitrate and platelet cGMP levels are decreased in patients with atrial fibrillation. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[26]  Y. Kagaya,et al.  Increased von Willebrand factor in the endocardium as a local predisposing factor for thrombogenesis in overloaded human atrial appendage. , 2001, Journal of the American College of Cardiology.

[27]  U. Goldbourt,et al.  Long-term prognosis of patients after a Q wave compared with a non-Q wave first acute myocardial infarction. Data from the SPRINT Registry. , 1996, European heart journal.

[28]  Christopher X. Wong,et al.  Assessment of endothelial function in atrial fibrillation: utility of peripheral arterial tonometry , 2012, Clinical and experimental pharmacology & physiology.

[29]  G. Hutchins,et al.  Coronary artery embolism and myocardial infarction. , 1978, Annals of internal medicine.

[30]  MattDewhurst,et al.  Regarding Article “Ethnic Distribution of Electrocardiographic Predictors of Atrial Fibrillation and Its Impact on Understanding the Ethnic Distribution of Ischemic Stroke in the Atherosclerosis Risk in Communities Study (ARIC)” , 2011 .

[31]  David M Herrington,et al.  Atrial fibrillation and the risk of myocardial infarction. , 2015, JAMA internal medicine.

[32]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[33]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[34]  Christopher X. Wong,et al.  Atrial platelet reactivity in patients with atrial fibrillation. , 2010, Heart rhythm.

[35]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[36]  S. Mondillo,et al.  Correlation between left atrial size, prothrombotic state and markers of endothelial dysfunction in patients with lone chronic nonrheumatic atrial fibrillation. , 2000, International journal of cardiology.

[37]  R. Califf,et al.  Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia , 1998 .

[38]  Michael Abdelnoor,et al.  Warfarin, aspirin, or both after myocardial infarction. , 2002, The New England journal of medicine.

[39]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[40]  G. Lip,et al.  Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. , 1995, British heart journal.

[41]  L. Chen,et al.  Comparable Ascertainment of Newly-Diagnosed Atrial Fibrillation Using Active Cohort Follow-Up versus Surveillance of Centers for Medicare and Medicaid Services in the Atherosclerosis Risk in Communities Study , 2014, PloS one.

[42]  K. Lee,et al.  Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. , 1998, Circulation.

[43]  A. Folsom,et al.  Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). , 2008, The American journal of cardiology.

[44]  P. Sanders,et al.  Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. , 2013, Journal of the American College of Cardiology.